Ethacrynic Acid Tablets USP
Failed Impurities/Degradation Specifications: Out of Specification for impurity 6 and total degradants.
14,806 recalls, newest first
Failed Impurities/Degradation Specifications: Out of Specification for impurity 6 and total degradants.
Failed dissolution specification: The dissolution test at the 24 month time point (end of shelf life) yielded an out of specification result.
Lack of Assurance of Sterility and Marketed without an approved NDA/ANDA: Product contains unapproved Cannabidiol and Curcumin
Lack of Assurance of Sterility and Marketed without an approved NDA/ANDA: Product contains unapproved Cannabidiol and Curcumin
Lack of Assurance of Sterility and Marketed without an approved NDA/ANDA: Product contains unapproved Cannabidiol and Curcumin
Lack of Assurance of Sterility and Marketed without an approved NDA/ANDA: Product contains unapproved Cannabidiol and Curcumin
Lack of Assurance of Sterility and Marketed without an approved NDA/ANDA: Product contains unapproved Cannabidiol and Curcumin
Failed Dissolution Specifications
Presence of Particulate Matter: confirmed customer complaint for the presence of particulate matter identified as iron oxide.
Short Fill
Discoloration: Out-of-specification results for appearance obtained during routine stability testing at the end of shelf-life for the parameters Appearance and Color of Solution.
Failed dissolution specifications: Low stage 3 results obtained for dissolution during routine stability testing.
Discoloration: product contains brown pellets
Presence of Particulate Matter: Fresenius Kabi recalling vials of Ketorolac
Defective Container: Sub-optimal crimping in vial of Pediatric Infuvite Multiple Vitamins
Presence of Particulate Matter - found in reserve sample vials at the firm.
Presence of Particulate Matter - found in reserve sample vials at the firm.
Labeling: Not elsewhere classified: Observed separation in the secondary packaging in the blister and the backer card
Labeling: Not elsewhere classified: Observed separation in the secondary packaging in the blister and the backer card
Labeling: Not elsewhere classified: Observed separation in the secondary packaging in the blister and the backer card
Product Mix-Up: a complaint received indicating mix-up of 10 mg Lisinopril tablets inside of 2 sealed bottles of 20 mg/1000 count bottles.
Failed Stability Specifications: Out-of-Specification (OOS) results for High Molecular Weight Polymers.
Chemical Contamination; product contains elevated levels of lead
CGMP Deviations: potential N-Nitrosodimethylamine (NDMA) amounts above levels established by the FDA.
Subpotent Drug: low out of specification (OOS) test result observed in long term stability study.